Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY)

100 filings reported holding INZY - Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share as of Q1 2024.
Inozyme Pharma, Inc. - Common stock, par value $0.0001 per share (INZY) has 87 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 49.9M shares of 64.5M outstanding shares and own 77.3% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (5.33M shares), Pivotal bioVenture Partners Investment Advisor LLC (4.49M shares), Sofinnova Investments, Inc. (4.28M shares), Rock Springs Capital Management LP (3.68M shares), EVENTIDE ASSET MANAGEMENT, LLC (3.18M shares), BlackRock Inc. (3.09M shares), SAMLYN CAPITAL, LLC (2.91M shares), Affinity Asset Advisors, LLC (2.64M shares), NEA Management Company, LLC (2.44M shares), and VANGUARD GROUP INC (2.42M shares).
This table shows the top 87 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.